It is well known that the spatial biology distribution ͑e.g., clonogen density, radiosensitivity, tumor proliferation rate, functional importance͒ in most tumors and sensitive structures is heterogeneous. Recent progress in biological imaging is making the mapping of this distribution increasingly possible. The purpose of this work is to establish a theoretical framework to quantitatively incorporate the spatial biology data into intensity modulated radiation therapy ͑IMRT͒ inverse planning. In order to implement this, we first derive a general formula for determining the desired dose to each tumor voxel for a known biology distribution of the tumor based on a linear-quadratic model. The desired target dose distribution is then used as the prescription for inverse planning. An objective function with the voxel-dependent prescription is constructed with incorporation of the nonuniform dose prescription. The functional unit density distribution in a sensitive structure is also considered phenomenologically when constructing the objective function. Two cases with different hypothetical biology distributions are used to illustrate the new inverse planning formalism. For comparison, treatments with a few uniform dose prescriptions and a simultaneous integrated boost are also planned. The biological indices, tumor control probability ͑TCP͒ and normal tissue complication probability ͑NTCP͒, are calculated for both types of plans and the superiority of the proposed technique over the conventional dose escalation scheme is demonstrated. Our calculations revealed that it is technically feasible to produce deliberately nonuniform dose distributions with consideration of biological information. Compared with the conventional dose escalation schemes, the new technique is capable of generating biologically conformal IMRT plans that significantly improve the TCP while reducing or keeping the NTCPs at their current levels. Biologically conformal radiation therapy ͑BCRT͒ incorporates patient-specific biological information and provides an outstanding opportunity for us to truly individualize radiation treatment. The proposed formalism lays a technical foundation for BCRT and allows us to maximally exploit the technical capacity of IMRT to more intelligently escalate the radiation dose.
I. INTRODUCTION
Intensity modulated radiation therapy ͑IMRT͒ has been used clinically to provide a highly conformal radiation dose to the target volume while reducing the doses to the surrounding sensitive structures.
1- 13 The current IMRT inverse planning is typically aimed at producing a homogeneous target dose under the assumption of uniform biology within the target volume. In reality, it is known that the spatial biology distributions in most tumors and normal tissues are rarely homogeneous. To maximize the efficacy of IMRT, it is desirable to take the inhomogeneous biological information into account and to produce customized nonuniform dose distributions on a patient specific basis. This type of radiation treatment is referred to as biologically conformal radiotherapy ͑BCRT͒. [14] [15] [16] [17] [18] [19] The simultaneous integrated boost ͑SIB͒ to elective volumes recently appearing in the literature 11, 17, 20 represents a simple example of BCRT. However, an underlying deficiency of the current SIB approach is that the boost doses are based on previous experience, not patient-specific biological information characterizing the spatial tumor burden distribution.
To establish the BCRT treatment planning scheme, three major aspects must be addressed: ͑i͒ Determination of the distribution of biological properties of the tumor and critical structures; ͑ii͒ Prescription of the desired dose distribution for inverse planning; and ͑iii͒ Inverse planning to generate most faithfully the prescribed nonuniform dose distribution. Recently spurred efforts in biological imaging, such as positron emission tomography ͑PET͒, single photon emission computed tomography ͑SPECT͒, and magnetic resonance spectroscopy imaging ͑MRSI͒, are aimed at providing solutions to the first problem. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] To give a few examples, the clonogen density in malignant glioma can be obtained based on the choline/creatine ratio through MRSI, 29, 30 tumor hypoxia can be quantified using PET imaging with fluorinated misonidazole ͑FMISO͒, 27, 28 tumor proliferation rate can be obtained based on the voxel activity level in DNA proliferation imaging ͑e.g., fluoro-L-thymidine PET͒, 25, 26, 32 and lung functional importance distributions can be obtained by perfusion imaging. 33 While the development of molecular imaging techniques is critically important in mapping out biology distributions, the successful integration of this information into IMRT planning through steps ͑ii͒ and ͑iii͒ is also indispensable to fully exploit the obtained biology information to improve patient care. In this study we focus our efforts on the last two problems, with the optimistic assumption that spatial biology distributions within a patient have already been determined from biological imaging or other means. Our goal is to establish a theoretical framework for quantitatively incorporating the biological data into IMRT inverse optimization, and to show the advantage of the selective dose escalation scheme in enhancing tumor control probability ͑TCP͒ and reducing the normal tissue complication probability ͑NTCP͒. In conjunction with the rapid development of molecular imaging techniques, this study lays a technical foundation for BCRT and provides a basis for clinically realizing the new treatment strategy in the future.
II. METHODS AND MATERIALS

A. Biological characterization and nonuniform target dose prescription
We assume that biological properties influencing radiation treatment are characterized phenomenologically by three radiobiology parameters: clonogen density ͑͒, radiosensitivity ͑␣͒, and proliferation rate ͑␥͒. Generally, these parameters are voxel dependent. In this work we concentrate on their spatial variation within tumor, and ignore the time dependence of the last two parameters.
To accomplish BCRT, an important step is to derive the desired dose distribution that maximizes the cell killing based on ͑ , ␣ , ␥͒ metrics. In the case of uniform biology, it is well known that the target dose should be uniformly distributed. It is, however, not clear at all what form of dose distribution should be used to maximize the cell killing for an arbitrary biology distribution. We start from a linear quadratic ͑LQ͒ model [34] [35] [36] with inclusion of the tumor cell proliferation. According to this model, the tumor clonogen survival S i in a voxel of volume V i after an irradiating dose D i is given by
is the initial clonogen density, d i is the fractional dose, ␣ i and ␤ i are the linearquadratic coefficients of the cell survival curve, ␥ i =ln 2/T p is the cell proliferation rate, T p is the potential cell doubling time, and ⌬T is the overall treatment time. The TCP of a voxel i can be expressed as
͑2͒
The TCP for the whole tumor is the product of the TCP i of all voxels within the tumor volume, i.e.,
For a given set of ͕ , ␣ , ␥͖, the task is to find the dose distribution that maximizes the TCP. Because of the limitation of normal tissue dose tolerances, an arbitrarily high dose to the tumor cannot be achieved and certain constraints need to be imposed. [36] [37] [38] [39] [40] [41] In line with previous researchers, 36,37,40 we restrict the integral dose to the tumor volume to a constant. Mathematically, the constraint is written as
where m i is the mass of voxel i, and E t is the integral target dose.
With the above formulation, the task becomes the maximization of the TCP under the constraint ͑4͒. The Lagrange multiplier method is employed to solve the problem. In this approach, a function
is introduced, where is the Lagrange multiplier, and the solution is obtained by solving the equations
When mass and volume are equal for all voxels in the target, using a process similar to Ebert and Hoban 40 ͑see the Appendix͒, we obtained a general formula for determining the desired dose, D 0 T ͑i͒, at the voxel i 
T ͑i͒ is then obtained using the updated d i . We find that D 0 T ͑i͒ converges to the solution in less than five iterations. In this study we set ␣ / ␤ = 10 Gy for all target voxels. The formalism proposed here is, however, general and can be extended to deal with nonuniform distributions of the ␣ / ␤ ratio.
B. Inverse planning with spatially nonuniform dose prescription
The next logical step after obtaining the calculated prescription dose is to use inverse planning to derive the optimal beam profiles that will produce the prescribed dose distribution. To proceed, we construct an objective function to take the known biological information into account. In addition to the voxel-specific prescription as determined by Eq. ͑7͒, the nonlinear dose responses of tumor and normal structures are considered using the concept of equivalent volume [42] [43] [44] [45] [46] [47] [48] of a voxel, which is defined as
where ͑⌬V eff ͒ i is the effective volume for voxel i with volume V i and dose D͑i͒, D t is the desired dose for a target voxel or the TD 5/5 of the corresponding organ, and ͑i͒ is the functional unit density. The value of n characterizes the dosevolume effect of an organ and reflects its architecture ͑serial or parallel͒ of the sensitive structure. It is obtained by fitting to clinical dose-volume data. For a sensitive structure, n is a positive number ͑n Ͼ 0͒ while for a target, n should be assigned with a small negative value ͑−1 Ͻ n Ͻ 0͒. ͑i͒ϵ1 for a target voxel. A general form of the inverse planning objective function in the voxel domain is written as
͑9͒
where r and r are the structure specific importance factors of target and sensitive structure , respectively, t and s the number of targets and sensitive structures, N and N the total number of voxels of target or sensitive structure , n and n the n parameter of target and sensitive structure , D c ͑i͒ the calculated dose in voxel i, D 0 T ͑i͒ the prescription dose in a target voxel i given by Eq. ͑7͒, and TD ,5/5 the TD 5/5 of sensitive structure . The objective function becomes the conventional quadratic objective function if the term in the bracket inside each summation is set to unity ͑this is true when the dose-volume effect is negligible, i.e., when n = n s = +ϱ͒. More detailed information about the optimization algorithm can be found in Ref. 49 .
C. Implementation
A software module for optimizing the objective function ͑9͒ is implemented in the platform of the PLUNC treatment planning system ͑University of North Carolina, Chapel Hill, NC͒. The dose calculation engine and a variety of image/ beam/plan display and evaluation tools of PLUNC are used to review and compare the optimization results. The ray-by-ray iterative algorithm ͑SIITP͒ reported earlier 50, 51 is employed to obtain the optimal beam intensity profiles. The dosevolume histograms ͑DVHs͒ of the involved organs are displayed at the end of each iterative step to visually monitor the optimization process.
D. Plan review tools
It is desirable to extend the currently used plan review tools to deal with a biologically heterogeneous system. For a target, we define the effective dose at a voxel as the physical dose normalized by the desired dose determined by Eq. ͑7͒. The effective-dose volume histogram ͑EDVH͒, which is obtained by replacing the dose with the effective dose in conventional DVH, is a useful tool for assessing BCRT plans. For a sensitive structure we replace the fractional volume by i V i to construct a functional dose volume histogram ͑FDVH͒, similar to that proposed by Lu et al. 52 and Marks et al. 33 After including the heterogeneous biological information into the EDVH or FDVH, the wisdom used in interpreting a conventional DVH can be applied to assess the BCRT plans. In addition to the effective dose and the EDVH or FDVH, a cluster of DVHs, each corresponding to a given set of biological parameters ͕ , ␣ , ␥͖, is also useful to assess dosimetric behavior of the system as a function of the biological status of the system.
Besides the dosimetric evaluation tools, we also used the TCP and NTCPs for plan evaluation. In calculating TCP and NTCP, the heterogeneous biology distributions need to be taken into account. TCP is calculated using Eqs. ͑2͒ and ͑3͒ and NTCP is assessed using Lyman's model. The KutcherBurman effective-volume DVH reduction method 44 is extended to include the nonuniform functional unit density distribution using Eq. ͑8͒ when transforming a nonuniform dose distribution into a uniform irradiation of an effective partial volume. Model parameters from Burman et al. 53 are listed in Table I for the NTCP calculation.
E. Case studies
A prostate case with two different hypothetical distributions of radiobiological parameters is used to test the proposed BCRT inverse planning scheme. In each study, the target consists of the prostate gland with a few intraprostatic lesions. The sensitive structures include the rectum, bladder, and femoral heads. Figures 1͑a͒and 3͑a͒ show the geometric shapes and locations of the structures in the two examples.
In the first example the target includes four biologically different regions, and the functional unit density distributions in the sensitive structures are uniform. Region 1 represents the basis reference target volume with typical parameters 54 prostatic lesions are listed in Table II . The parameters n characterizing the dose-volume effect of the sensitive structures in the objective function ͑9͒ can be found in Table I . The parameter n is chosen to be −0.2. For comparison, five IMRT plans, indexed by plan 1, -2, -3, -4, and -5, are generated. Plan 1 is obtained using the BCRT optimization scheme described above with D ref = 70 Gy. Plan 2 is obtained by prescribing the whole target a uniform dose of 70 Gy. Plan 3 and -4 are similar to plan 2 except that the dose is escalated to 81 and 91 Gy, 12, 14 respectively. Plan 5 is the SIB IMRT plan with the same prescribed doses as that of the BCRT. In plan 1 to -4, the objective function expressed in Eq. ͑9͒ is used and in plan 5 the conventional dose-based quadratic objective function is adopted. The optimization parameters ͑maximum dose constraints and importance factors͒ in the dose-based method were adjusted by trial and error to obtain the "optimal" plan. The same beam configuration ͑five equally spaced 15 MV photon beams with gantry angles of 0°, 72°, 144°, 216°, and 288°in IEC convention͒ is used in generating the five plans.
In the second example we hypothetically introduced a higher functional unit density region in the rectum ͓Rគregion 2 as shown in Fig. 3͑a͔͒ in addition to three biologically different target regions. The functional unit density of the Rគregion 1 is assigned a value of 1 and that of the Rគregion 2 is set to be 4. The same set ͑ 0i , ␣ i , ␥ i ͒ as the previous example and a reference dose of 70 Gy are assigned to the prostate gland. The parameters for other target regions are listed in Table II . Once again, five IMRT plans are generated: Plan 1 is obtained using the proposed selective dose escalation scheme, plan 2, -3, and -4 are generated using different uniform prescription doses ͑70, 81, and 91 Gy͒ and plan 5 is SIB plan with the same prescription as plan 1 but is optimized using the conventional quadratic objective function. In generating these five plans, seven equally spaced 15 MV photon beams ͑0°, 51°, 103°, 154°, 206°, 257°, and 309°͒ are employed.
III. RESULTS
A. Example 1: Prostate case with four biologically different regions
In the first example, based on Eq. ͑7͒ and the parameters listed in Table II , the prescription doses to the target region 2, 3, and 4 are determined to be 85, 119, and 75 Gy, respectively. In order to examine the capability of the BCRT inverse planning system in producing an extremely nonuniform dose within a target volume, we have used an "extreme" combination of ͕ , ␣ , ␥͖, which leads to an exceedingly high prescription dose in region 3 ͑119 Gy͒. Figures 1͑b͒-1͑d͒ show the isodose distributions of plan 1 in a transverse slice and two sagittal slices. The EDVH of the target and the DVHs of the sensitive structures are plotted in Fig. 2 for plan 1 in solid curves. For comparison, the corresponding EDVHs and DVHs of plan 2, -3, -4, and -5 are also shown in the figures as dashed, dotted, dash-dotted, and dash-dot-dotted curves, respectively. As seen from Fig. 1 , all regions in the prostate are well covered by their prescription doses and the sensitive structures are well spared. Even in this extreme case, it seems that the inverse planning system can satisfy the biological requirement. A steep dose gradient is found at the interface between the target and the rectum. A comparison of the target EDVH in Fig. 2͑a͒ indicates that above 98.5% of the target voxels achieved their desired doses in plan 1 and plan 5. However, for the uniform dose escalation scheme, the desired doses in some regions ͑region 2, 3 and part of region 4 in plan 2; region 2 and 3 in plan 3; and region 3 in plan 4͒ are not achieved. We found that, in plan 1, the doses to the surrounding sensitive structures are not significantly increased compared with those of plan 2, despite the fact that some voxels in region 4 receive a dose as high as 119 Gy. In plan 1, the rectum, bladder, and femoral heads are better spared in comparison with plan 3 and -4. However, by comparing the DVHs of plan 1 and -5, it is noticed that, although the target coverage in plan 5 is similar to that in plan 1, the sensitive structures in plan 5 receive much higher doses than plan 1, indicating that the proposed approach can improve the sensitive structure sparing compared with the conventional dose-based quadratic objective function. In addition, as can be expected, the target doses in plan 1 and -5 are less uniform in the target volume in comparison with that of plan 2, -3, and -4. This is more pronounced in the target region 1, where about 50% of the volume receives a dose larger than 85 Gy as shown in Fig. 2͑b͒ , resulting in an effective dose above 120% in ϳ50% of the target voxels ͓see Fig. 2͑a͔͒ . However, the increase of dose inhomogeneity is desirable here provided that the NTCPs are not compromised. Table III lists the calculated TCPs for the targets and NTCPs for the sensitive structures with consideration of heterogeneous biology in all plans. It is seen that the overall TCPs for the three plans with uniform target dose prescriptions ͑plan 2, -3, and -4͒ are all less than that of the BCRT plan ͑plan 1͒ and SIB plan ͑plan 5͒. This is understandable because, in plan 2, -3 and -4, some target regions ͑such as target region 3͒ receive doses much less than the desired doses. For example, in plan 4, the TCP for target region 3 is only 0.461. Even if the TCPs for region 1, 2, and 4 are all close to 1.00, the resultant total TCP for plan 4 is 0.461. In contrast, the TCPs of plan 1 and plan 5 are 0.984 and 0.981, respectively. Furthermore, we found that the NTCPs of the sensitive structures in plan 1 are very close to plan 2, significantly less than plan 3, -4, and -5. For example, the rectum NTCPs are 0.21% for plan 1 and 0.20% for plan 2. These are increased to 0.65%, 1.84%, and 0.89% for Plan 3, -4, and -5, respectively. Again, although similar overall TCPs are achieved for the BCRT and dose-based SIB IMRT plans when the same dose prescriptions are used, the rectum NTCPs are significantly reduced using the proposed formulism. This is consistent with our previous study of the objective function in the context of conventional IMRT aiming to deliver a uniform dose to the target volume.
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B. Example 2: Prostate case with three biologically different regions and nonuniform importance in rectum
In the second hypothetical example, there are three biologically different regions in the prostate and two functionally different regions in the rectum. The prescription doses for the three target regions are 70 ͑reference dose͒, 99, and 121 Gy, as determined by Eq. ͑7͒ with the biological parameters listed in Table II . Figures 3͑b͒-3͑f͒ show the isodose distributions of plan 1 in three transverse slices and two sagittal slices. The EDVHs and DVHs of the target and sensitive structures for plan 1 to plan 5 are plotted in Fig. 4 as solid, dashed, dotted, dash-dotted, and dash-dot-dotted curves, respectively. Similar to the previous example, in plan 1, all regions in the prostate are well covered by a dose comparable to the prescription and the sensitive structures are well spared. The dose gradient at the interface between the target and the rectum is very sharp for all the plans. From Fig. 4͑a͒ we find that above 98% of the target voxels achieved their desired doses in plan 1. As a consequence of incorporating functional unit density information in inverse planning, the rectum sparing is even better than that of plan 2, much better than that of plan 3, -4. However, we notice that the sparing of the femoral heads in plan 1 is not as good as that in plan 2, -3, and -4. This is because high-intensity beamlets that pass through the femoral heads are needed to adequately irradiate the target region 3, as seen from Figs. 3͑b͒ and 3͑c͒. In addition, similar to the first example, the target coverage in plan 5 is close to that in plan 1, but the doses to the sensitive structures in plan 5 are much higher than that in plan 1. Table IV lists the calculated TCPs and NTCPs for all plans. Once again, we found that the TCP of the target in the proposed BCRT technique is much higher and the NTCP of the rectum is lower compared with those obtained using the conventional uniform dose escalation schemes. Remarkably,
FIG. 2. Comparison of EDVHs and
DVHs of the BCRT plan ͑plan 1͒, three uniform IMRT plans ͑plan 2: 70 Gy, plan 3: 81 Gy, and plan 4: 91 Gy͒ and the SIB plan ͑plan 5͒ in example 1. ͑a͒ Target EDVHs for the five plans ͑insert is the regular DVHs of the prostate target͒. The normalized doses to the target region 1, 2, 3 and 4 are 70, 85, 119, and 75 Gy, respectively; ͑b͒-͑e͒ DVHs of different target regions and sensitive structures for the five plans. The solid, dashed, dotted, dash-dotted, and dash-dot-dotted curves represent the results of plan 1, 2, 3, 4, and 5, respectively. The effective dose is defined as the physical dose at a voxel normalized by its desired dose determined by Eq. ͑7͒.
the overall TCP for the target is increased from 0.823 to 0.982 and the NTCP of the rectum is reduced from 3.1% to 0.40% when plan 4 is replaced by the selective dose escalation scheme ͑plan 1͒. Again, we found that, for similar overall TCPs, the rectum NTCPs of the BCRT plan are much lower in comparison with that obtained using dose-based SIB scheme.
IV. DISCUSSION
Equation ͑7͒ provides a general formula for determining the desired target dose distribution based on the known biology information of the system, and represents one of the main results of this study. A few special cases are worth discussing here. First, when the biology distribution is uniform in the target, a uniform dose of D ref is desired. This is consistent with previous studies 37 and existing clinical knowledge.
When the clonogen density is nonuniform while the values of ␣ and ␥ are constant across the target, we have
which is identical to the formula obtained by Webb and Nahum. 36 Equation ͑10͒ indicates that the desired dose depends on the tumor cell density logarithmically and is thus relatively insensitive to a variation in the clonogen density. For ␣ ref = 0.312, for example, even if the clonogen density in a tumor voxel is 10 times higher than that of the reference situation, the desired dose is only about 7 Gy higher than the reference value. A detailed discussion of this special situation has been presented by Webb and Nahum. 36 Another special case is that the tumor clonogen density and the proliferation rate are constant and the radiosensitivity ␣ is spatially nonuniform. Equation ͑7͒ now becomes
͑11͒
The desired dose is approximately inversely proportional to the parameter ␣ i Ј and is thus sensitively dependent on the value of parameter ␣ i Ј. This is similar to the conclusions of If we keep the tumor clonogen density and radiosensitivity ␣Ј constant and only allow the proliferation rate ␥ to vary spatially, then
Thus, the desired dose increases linearly with the proliferation rate. In this work the potential cell-doubling times, T p , used by King et al. 54 are adopted. Since T p for a prostate tumor is relatively longer, its influence on the desired dose is not very significant. However, for other more rapidly proliferating tumors, the proliferation rate may play an important role. In such situations, reducing the overall treatment time ⌬T ͑e.g., using an accelerated scheme͒ is helpful to minimize the influence of the proliferation rate. We emphasize that the quadratic term in the linearquadratic model plays an important role in accounting for the fractionation effect. If only the linear term is kept, the total dose D 0 T ͑i͒ in Eq. ͑7͒ is no longer entangled with the fractional dose d i . When the quadratic term is "switched on," the value of D 0 T ͑i͒ depends not only on the total reference dose but also on the fractional dose. For a large fractional dose, the total dose will be less, and vice versa. In other words, the total dose received by a voxel is determined by two contributing factors, one being the local biological parameters ͕ , ␣ , ␥͖, and the other being the coupling between the fractional dose and the total dose. The latter is responsible for the phenomenon that the total dose needs to be decreased when the number of fractions is reduced. If the quadratic term were ignored, according to Eq. ͑7͒, the dose required at a voxel would be much higher. For example, the desired doses for target region 3 in example 1 are determined to be 119 and 135 Gy with and without inclusion of the quadratic term, respectively.
We also would like to emphasize that in this study, the radiosensitivity ␣Ј and proliferation rate ␥ are assumed to be constants during the whole treatment course. In reality, both ␣Ј and ␥ may change with time due to such biological pro- FIG. 3 . A hypothetical prostate case with three biologically different regions and nonuniform importance in the rectum ͑example 2͒. ͑a͒ Geometric shapes and locations of the targets and sensitive structures; ͑b͒-͑d͒ Isodose distributions in three axial slices and two sagittal slices for plan 1, generated by optimizing the objective function with nonuniform dose prescription derived from Eq. ͑7͒.
cesses as tumor cell redistribution 56 and reoxygenation. 57 The time dependence of these factors may result in a reduction of the desired prescription dose, and this effect should be investigated in the future.
Comparing with the uniform dose escalation scheme, our study clearly suggests that deliberately incorporating an inhomogeneous dose distribution significantly enhances the TCP and reduces the NTCP. Physically, we believe that the FIG. 4 . Comparison of EDVHs, FDVHs, and DVHs of the BCRT plan ͑plan 1͒, three uniform IMRT plans ͑plan 2: 70 Gy, plan 3: 81 Gy, and plan 4: 91 Gy͒ and the SIB plan ͑plan 5͒ in example 2. ͑a͒ The target EDVHs for the five plans ͑insert is the regular DVHs of the prostate target͒. The normalized doses to the target region 1, 2, and 3 are 70, 99, and 121 Gy, respectively; ͑b͒ The rectum FDVHs for the five plans ͑insert is the regular DVHs of the rectum͒; ͑c͒-͑e͒: DVHs of different target regions and sensitive structures for the five plans. The solid, dashed, dotted, dash-dotted, and dash-dot-dotted curves represent the results of plan 1, 2, 3, 4, and 5, respectively. significant improvement arises from the more effective use of radiation in the newly proposed treatment scheme. A great deal of dose is "wasted" in the conventional uniform dose escalation scheme. For example, in the first example the increased doses in the target region 1 and 4 have almost no contributions to the enhancement of the TCP when plan 2 ͑70 Gy uniform dose to the prostate gland͒ is replaced by plan 3 ͑81 Gy͒ or plan 4 ͑91 Gy͒. Even though part of the prostate receives high doses in the selective dose escalation scheme ͑for example, 119 Gy in target region 3 of the first example͒, the total deposited energy in the targets is still less than that of plan 3 or -4. It is thus not difficult to understand why deliberately nonuniform dose distributions can, in general, reduce the radiation side effects and represent a more intelligent way to irradiate the tumor target.
A similar deficiency also exists in the current SIB approach. Although it is clear that the regions with different tumor burdens should be given different doses, the specific values for the regions are determined in an ad hoc manner. The empirical boost dose could be too low, in which case the tumor control is sacrificed, or too high, in which case other parts of the system are compromised. The problem is aggravated when the tumor burden varies continuously from point to point. In the proposed BCRT approach, the prescribed dose is voxel dependent and is determined based on the tumor biology distribution. In addition, a more sophisticated objective function is developed to take the dose-volume effect and functional density information of the sensitive structures into account, resulting in better sparing of the sensitive structures.
Finally, it should be recognized that our knowledge of radiobiological parameters for tumors or normal tissues is still very crude and the validity of the model is still under establishment. Therefore, the LQ model and the parameters adopted in the paper are fine for a proof of principle but they should not be taken as more than that.
V. CONCLUSION
In the presence of nonuniform biology distributions, IMRT inverse planning is complicated by the fact that it is not clear what represents the appropriate spatial dose prescription, which is generally used as a landmark to guide the dose optimization process. In this work, we have described a technique for deriving the prescription dose based on an LQ model with consideration of the cell proliferation. The relation is quite general and can be used as prescription dose to guide an arbitrary inverse planning objective function aimed to produce customized dose distribution in accordance with the spatial biology information. For a given patient, IMRT inverse planning now consists of two steps: Derivation of the prescription dose, and beam profile optimization that produces as closely as possible this prescription dose. The formalism proposed here lays a technical foundation for future BCRT development, allowing us to escalate tumor dose more intelligently and effectively. When combined with state-ofthe-art biological imaging techniques, which promise to reveal detailed patient-specific biology distribution information, this study may have significant implication for the management of cancer in the future.
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APPENDIX: DERIVATION OF EQUATION "7…
We present the detailed derivation process for Eq. ͑7͒ under the condition of equal mass and volume for all target voxels.
Substituting Eq. ͑5͒ into Eq. ͑6͒, we obtain 
͑A4͒
The desired doses, D 0 T ͑i͒, producing maximum TCP with the constraint of constant integral dose, can be obtained by substituting TCP i and TCP ref expressed in Eq. ͑2͒ into Eq. ͑A4͒
͑A5͒
When volume for all target voxels is equal, Eq. ͑A5͒ becomes Eq. ͑7͒. 
